AstraZeneca PLC


RNS Number : 1271O
AstraZeneca PLC
26 May 2015

AstraZeneca Provides Update on Brodalumab Development Programme



Amgen has announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The announcement follows Amgen's decision to concentrate on other portfolio priorities after observing suicidal ideation and behaviour events in the brodalumab programme which may result in restrictive labelling.


AstraZeneca will confirm its decision on the future development of brodalumab as soon as possible, based on further review of the data.


Briggs Morrison, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "Data from the three AMAGINE Phase III pivotal studies highlighted that brodalumab has an effective mechanism of action that delivers clinical benefit. We will fully evaluate the data and assess all options before we make our independent decision about the future of this potential medicine."



About Brodalumab (AMG 827)

Brodalumab is a novel human monoclonal antibody that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor. By stopping IL-17 ligands from activating the receptor, brodalumab prevents the body from receiving signals that may lead to inflammation. The IL-17 pathway plays a central role in inducing and promoting inflammatory disease processes.


About the Amgen and AstraZeneca Collaboration


In April 2012, Amgen and AstraZeneca formed a collaboration to jointly develop and commercialise five monoclonal antibodies from Amgen's clinical inflammation portfolio.  With oversight from joint governing bodies, Amgen leads clinical development and commercialisation for brodalumab and AMG 557/MEDI5872 (Phase Ib for autoimmune disease, such as systemic lupus erythematosus).  AstraZeneca, through its biologics arm MedImmune, leads clinical development and commercialisation for MEDI7183/AMG181 (Phase II for ulcerative colitis and Crohn's disease), MEDI2070/AMG139 (Phase II for Crohn's disease) and MEDI9929/AMG157 (Phase II for asthma).


About AstraZeneca


AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:





Media Enquiries

Esra Erkal-Paler                          +44 20 7604 8030 (UK/Global)

Vanessa Rhodes                         +44 20 7604 8037 (UK/Global)

Ayesha Bharmal                          +44 20 7604 8034 (UK/Global)

Jacob Lund                                  +46 8 553 260 20 (Sweden)

Michele Meixell                             + 1 302 885 6351 (US)


Investor Enquiries

Thomas Kudsk Larsen

+44 20 7604 8199   

mob: +44 7818 524185

Eugenia Litz

Respiratory, Inflammation and Autoimmunity

+44 20 7604 8233   

mob: +44 7884 735627

Nick Stone

Cardiovascular and Metabolic Disease

+44 17 6326 3994   

mob: +44 7717 618834

Karl Hård


+44 20 7604 8123

mob: +44 7789 654364

Craig Marks

Infection, Neuroscience and Gastrointestinal Disease

+44 20 7604 8591  

mob: +44 7881 615764

Christer Gruvris

+44 20 7604 8126

mob: +44 7827 836825



26 May 2015


This information is provided by RNS
The company news service from the London Stock Exchange